miRagen Therapeutics Finds $20M

Boulder-based miRagen Therapeutics, which is developing biopharamceuticals for treating cardiovascular and muscle disease, said Tuesday that it has raised $20M in a Series B funding round. The round was led by Remeditex Ventures, and also included Atlas Venture, Boulder Ventures Ltd., Amgen Ventures, and Broadview Ventures. miRagen, whic his headed by William S. Marshall, said the funding will go towards development of its pipeline. More information »